Clovis Oncology Inc (NASDAQ:CLVS)
| 5.87 Delayed Data As of May 14 |  +0.245 / +4.36%Today’s Change | 4.08 Today|||52-Week Range 11.10 | +22.19% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Operating Activities | Net Income / Starting Line | -89.9M | -99.3M | -86.4M | -120.4M | |
| Depreciation | 990.0K | 2.1M | 1.7M | 1.9M | ||
| Total Other Cash Flow | 12.0M | 12.3M | 14.2M | 34.7M | ||
| Funds From Operations | -76.9M | -84.9M | -70.5M | -83.8M | ||
| Funds From/For Other Operating Expenses | -4.5M | -2.1M | 27.9M | 14.2M | ||
| Net Cash Flow - Operating Activities | -72.4M | -82.7M | -98.5M | -98.0M | ||
| Investing | Increase In Investments | -195.0M | -180.0M | -138.4M | -67.4M | |
| Decrease In Investments | 95.0M | 195.0M | 153.5M | 143.3M | ||
| Capital Expenditures | -5.6M | -1.5M | -1.2M | -253.0K | ||
| Net Cash Flow Investing | -105.6M | 13.5M | -1.1M | 75.0M | ||
| Financing | Short Term Borrowings | 0.00 | -245.0K | 0.00 | 0.00 | |
| Long Term Borrowings | -148.0K | 0.00 | 0.00 | 6.9M | ||
| Long Term Debt Reduction | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Proceeds Stock Sale | 740.0K | 770.0K | 1.1M | 1.4M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | -- | -- | -- | -- | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 35.0K | 0.00 | 0.00 | ||
| Net Cash Flow - Financing | 592.0K | 490.0K | 1.1M | 8.3M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -79.0K | -261.0K | -64.0K | 107.0K | |
| Net Change In Cash | -177.4M | -68.7M | -98.5M | -14.8M | ||
